SeaStar Medical Q3 2026 Earnings Date & Estimates

SeaStar Medical (NASDAQ:ICU) is a medical device company focused on developing and commercializing therapies for conditions associated with excessive inflammation, including acute kidney injury and other critical illnesses. The company’s technology is designed to target activated immune cells and reduce the inflammatory response that can contribute to organ damage.

Its lead product is the Selective Cytopheretic Device (SCD), an extracorporeal blood-processing device intended to be used with continuous renal replacement therapy. The SCD is designed to selectively target and modulate activated neutrophils and monocytes, which may help reduce the production of harmful inflammatory cytokines while preserving normal immune function.

SeaStar Medical has also developed the SCD-PEDS, an iteration intended for pediatric patients with acute kidney injury who require continuous renal replacement therapy. The U.S. Food and Drug Administration granted the SCD-PEDS Humanitarian Device Exemption in 2023. The company is headquartered in Denver, Colorado, and its activities have primarily centered on research, clinical development, regulatory efforts, and commercialization of its SCD technology in the United States.